

1 February 2024

EXTENSION OF ENTITLEMENT OFFER CLOSING DATE

HeraMED Limited (ASX:HMD) (**HeraMED** or **the Company**) refers to the offer booklet released to ASX on 18 January 2024 (**Offer Booklet**) and the entitlement and acceptance form (or a letter advising where to access those documents) for the non-renounceable pro-rata entitlement issue of 1 new Share for every 5 existing Shares held by Eligible Shareholders on the Record Date, at an issue price of \$0.02 per New Share to raise up to approximately \$1.28 million (before costs) (**Entitlement Offer**) that was dispatched to eligible shareholders on 29 January 2024.

The Company advises that it has extended the closing date of the Entitlement Offer from 5.00pm (Sydney time) on Wednesday, 7 February 2024 to 5.00pm (Sydney time) on Friday, 23 February 2024.

The new timetable with the extended Closing Date and other consequential date changes is as follows:

Last day to extend the Closing Date	20 February 2024
Closing Date (5.00pm Sydney time)	23 February 2024
Unless otherwise determined by ASX, New Shares quoted on a deferred settlement basis from market open	26 February 2024
Last day for HeraMED to announce results of the Offer, issue New Shares taken up under the Offer and to lodge an Appendix 2A with ASX to notify ASX of the issue of New Shares and apply for their quotation (Before noon (Sydney time))	28 February 2024

**The dates above are indicative only and subject to change. Subject to the Corporations Act and ASX Listing Rules, HeraMED reserves the right to amend this indicative timetable by making an announcement to ASX. In particular HeraMED reserves the right to extend the Closing Date or withdraw the offer without notice by making an announcement to ASX. Any extension of the Closing Date will have a consequential effect on the anticipated date for the issue of New Shares under the Offer.*

If you have any questions, please contact the Company at the details set out below.

--ENDS--

Authorised by the Board of HeraMED Limited.

For more information please contact:

HeraMED Limited
Executive Chairman
Dr Ron Weinberger
M: +61 406 384 189
E: ron@hera-med.com

Company Secretary
Jonathan Hart
E: Jonathan@hera-med.com

Investor Relations
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

-ENDS-